The Naked Truth About GLP-1 Weight-Loss Drugs

What’s the Difference Between Ozempic®, Wegovy®, Mounjaro®, Zepbound®, Saxenda®, and the Next Generation of Weight-Loss Medications?

A 2026 Update on Semaglutide, Tirzepatide, Liraglutide, and Retatrutide

Editor’s Note and Acknowledgment

This article was inspired by and builds upon the excellent patient-oriented overview originally published by Dory Zayas on RealSelf in November 2023, “The Differences Between Ozempic, Wegovy, Mounjaro, Saxenda, and Other Popular Weight-Loss Drugs.”

The original RealSelf article helped explain an emerging and often confusing group of medications at a time when GLP-1 drugs were rapidly entering public awareness.

A great deal has changed since 2023.

This article is an independent 2026 update and summary for The Naked Truth About Plastic Surgery Series. It incorporates newer clinical evidence and developments involving semaglutide, tirzepatide, retatrutide, and other metabolic medications, while also addressing an issue that has become increasingly important in plastic surgery: what happens to the face and body after substantial medication-assisted weight loss?

The Naked Truth

Ozempic®, Wegovy®, Mounjaro®, and Zepbound® are often discussed as though they are interchangeable “GLP-1 drugs.” They are not. Some medications contain the same active ingredient but have different FDA-approved indications. Others work through different combinations of metabolic receptors. And the newest investigational drugs are moving beyond GLP-1 alone. The easiest way to understand the evolution is:

Liraglutide → GLP-1

Semaglutide → GLP-1

Tirzepatide → GIP + GLP-1

Retatrutide → GIP + GLP-1 + glucagon

In general, clinical trials have demonstrated progressively greater average weight reduction as obesity pharmacotherapy has evolved from older GLP-1 drugs to newer dual- and triple-receptor approaches. However, more receptors do not automatically mean that a medication is better for every patient.

The right medication depends on the patient’s medical history, degree of obesity, diabetes status, cardiovascular risk, side effects, treatment goals, insurance coverage, cost, and individual response.

The Major Weight-Loss Medications Compared

Medication	Common Brand	Receptors	Frequency	Primary Role	Relative Weight-Loss Effect
Liraglutide	Saxenda®, Victoza®	GLP-1	Daily	Obesity/diabetes depending on brand	Moderate
Semaglutide	Wegovy®, Ozempic®, Rybelsus®	GLP-1	Usually weekly injection; oral formulations also exist	Obesity/diabetes depending on product	High
Tirzepatide	Zepbound®, Mounjaro®	GIP + GLP-1	Weekly	Obesity/diabetes depending on brand	Very high
Retatrutide	Investigational	GIP + GLP-1 + glucagon	Weekly in trials	Investigational obesity/metabolic therapy	Potentially very high

Weight-loss percentages should not be compared as though all studies were identical. Clinical trials differ in patient populations, doses, duration, diabetes status, and statistical methodology.

Liraglutide: The Earlier Generation

Liraglutide is a GLP-1 receptor agonist marketed as Saxenda® for chronic weight management and Victoza® for type 2 diabetes.

It was an important advance in medical weight management, but it requires daily injections and generally produces less average weight loss than the newer medications.

Liraglutide helped establish an important principle: manipulating the body’s natural appetite and metabolic signaling could produce clinically meaningful weight loss without surgery.

Its principal disadvantage today is that newer medications can generally achieve greater average weight reduction with more convenient weekly administration.

Semaglutide: The Drug That Changed the Conversation

Semaglutide brought GLP-1 medications into mainstream culture.

Ozempic® and Wegovy® both contain semaglutide, but they are not simply interchangeable brand names. They have different FDA-approved indications and dosing strategies.

Semaglutide activates the GLP-1 receptor. Among its effects, it increases satiety, reduces appetite, improves glucose-dependent insulin secretion, and slows gastric emptying.

The landmark STEP 1 trial reported an average body-weight reduction of approximately 14.9% at 68 weeks with semaglutide 2.4 mg in adults with overweight or obesity without diabetes.

That degree of weight reduction was a major change in what physicians could realistically expect from nonsurgical obesity treatment.

The semaglutide story also continues to evolve. In 2026, the FDA approved a higher-dose semaglutide injection for chronic weight management in certain adults.

Tirzepatide: Adding a Second Metabolic Pathway

Tirzepatide represents the next major step.

Rather than acting only on GLP-1 receptors, tirzepatide activates:

GIP + GLP-1 receptors.

It is marketed as Mounjaro® for type 2 diabetes and Zepbound® for chronic weight management.

This dual-receptor mechanism has translated into greater average weight reduction than older GLP-1 therapy in clinical studies.

Most importantly, we now have direct comparative evidence rather than simply comparing separate clinical trials. Head-to-head research comparing tirzepatide with semaglutide demonstrated greater average weight reduction with tirzepatide in the studied population.

For appropriate patients, tirzepatide has therefore become one of the most effective established pharmacologic treatments for obesity.

Retatrutide: The Next Generation?

Retatrutide may represent another major change.

Instead of targeting one or two metabolic receptors, retatrutide activates three:

GIP + GLP-1 + glucagon.

This has led to the description of retatrutide as a triple agonist.

The addition of glucagon receptor activity is particularly interesting because it may affect energy expenditure and lipid metabolism in addition to appetite, satiety, and glucose regulation.

Early clinical trials produced remarkable weight-loss results, and more recent Phase 3 findings have further increased interest in the drug.

However, there is an extremely important distinction patients need to understand:

Retatrutide remains investigational as of this update.

It should not be confused with an FDA-approved medication that can simply be substituted for Wegovy or Zepbound.

Why Doesn’t Everyone Take the Most Powerful Drug?

Because treating obesity is more complicated than selecting the medication associated with the largest number on a clinical trial graph.

Patients respond differently.

The best treatment may depend upon:

• Amount of weight that needs to be lost
• Whether the patient has type 2 diabetes
• Whether the patient has cardiovascular disease
• Whether the patient has sleep apnea
• Other medications
• Gastrointestinal tolerance
• Gallbladder or pancreatic history
• Nutritional status
• Age and muscle mass
• Cost and insurance coverage
• Ability to remain on long-term treatment
• Individual response to the medication

More weight loss is also not automatically better.

The goal should be better health and better body composition, not simply the lowest possible number on a scale.

The Part of the GLP-1 Story We Don’t Talk About Enough: Muscle

One of the most important lessons emerging from the GLP-1 era is that weight loss and fat loss are not the same thing.

When people lose substantial amounts of weight, they generally lose some combination of fat and lean tissue.

That means a patient can lose 40, 60, or even 100 pounds and simultaneously lose meaningful muscle mass.

This becomes especially important in older patients.

Patients undergoing substantial medical weight loss should therefore discuss adequate protein intake, resistance exercise, nutrition, and preservation of lean body mass with their treating clinicians.

The objective should increasingly be:

Lose excess fat while preserving muscle and metabolic health.

What Happens When You Stop?

Another misconception is that patients can necessarily take these medications for several months, reach their goal weight, and simply discontinue treatment.

Obesity is increasingly understood as a chronic disease.

Clinical research with semaglutide has demonstrated substantial weight regain after treatment withdrawal in many patients.

That does not mean every patient must remain on the same dose forever. It does mean that physicians and patients should think about a maintenance strategy from the beginning.

Long-term management may involve medication, nutrition, exercise, resistance training, behavioral changes, and continued medical monitoring.

What About Compounded Semaglutide and Tirzepatide?

This is another area where information from 2023 needs updating.

During medication shortages, compounded versions of semaglutide and tirzepatide became widely available.

Patients should understand that a compounded medication is not the same thing as an FDA-approved branded medication from a regulatory standpoint.

Compounded drugs do not undergo FDA premarket review for safety, effectiveness, manufacturing quality, and consistency in the same manner as approved products.

The FDA has specifically warned about unapproved GLP-1 products, dosing errors, and inappropriate semaglutide salt formulations.

Patients considering compounded medication should know exactly what they are receiving, who manufactured it, what pharmacy dispensed it, and why a compounded product is medically appropriate.

The Plastic Surgery Connection

This is where the GLP-1 revolution intersects directly with plastic surgery.

These medications can reduce fat.

They cannot reliably shrink excess skin.

When someone loses 20%, 25%, or more of their body weight, the skin and supporting tissues may not contract sufficiently to accommodate the body’s smaller size.

The result may include:

Face: hollow cheeks, temporal hollowing, jowling, neck laxity, and loss of facial volume.

Breasts: deflation, loose skin, loss of upper-pole fullness, and breast ptosis.

Abdomen: loose abdominal skin, lower abdominal folds, and more visible muscle separation.

Arms and thighs: hanging or crepey skin.

Buttocks: loss of projection and deflation.

These changes are frequently described using terms such as “Ozempic face,” “Ozempic breasts,” and “Ozempic butt.”

Those terms are catchy but somewhat misleading.

The medication itself is not necessarily causing these anatomical changes. Major weight loss is.

Similar changes have long been observed following bariatric surgery and other forms of substantial weight reduction.

When Should Plastic Surgery Be Considered?

Losing weight and treating the consequences of weight loss are two different stages.

For patients considering surgery, I generally want to think beyond the number on the scale.

Important considerations include:

Is the patient’s weight reasonably stable?

Is the patient still actively losing significant weight?

Is nutrition adequate?

Has muscle mass been preserved?

Is the patient medically healthy enough for elective surgery?

What will happen to the result if another 20 or 30 pounds are lost?

Depending upon the patient’s anatomy, treatment after substantial weight loss may include facial rejuvenation, facelift or neck lift, breast lift, breast augmentation, abdominoplasty, body lift, arm lift, thigh lift, or combinations of these procedures.

The correct procedure depends upon what changed—not simply how much weight was lost.

The Naked Truth

GLP-1 medications have fundamentally changed the treatment of obesity.

But Ozempic, Wegovy, Mounjaro, Zepbound, and the emerging generation of drugs are not interchangeable.

The progression can be understood simply:

Liraglutide: GLP-1

Semaglutide: GLP-1

Tirzepatide: GIP + GLP-1

Retatrutide: GIP + GLP-1 + glucagon

As these medications become more effective, we need to expand the conversation beyond “How much weight can I lose?”

We should also be asking:

How much of that weight is fat?

How much muscle am I preserving?

What happens when I stop treatment?

Can I maintain the result?

What happens to my skin, face, and body after major weight loss?

And finally:

What can medicine correct—and what requires surgery?

That is the part of the GLP-1 revolution that plastic surgeons will increasingly be asked to address.

Frequently Asked Questions

1. Are Ozempic and Wegovy the same drug?

Both contain semaglutide, but they are FDA-approved and dosed for different indications. Wegovy is specifically indicated for chronic weight management in appropriate patients, while Ozempic is primarily a diabetes medication with additional approved cardiometabolic indications.

2. Are Mounjaro and Zepbound the same medication?

Both contain tirzepatide. Mounjaro is primarily indicated for type 2 diabetes, while Zepbound is indicated for chronic weight management in appropriate patients and has additional indications.

3. Which currently approved medication generally produces the greatest weight loss?

Among the established FDA-approved medications discussed here, tirzepatide generally produces greater average weight loss than semaglutide. Individual responses vary substantially.

4. Why might tirzepatide produce more weight loss than semaglutide?

Semaglutide activates GLP-1 receptors, whereas tirzepatide activates both GIP and GLP-1 receptors. Head-to-head clinical research has demonstrated greater average weight reduction with tirzepatide in studied patients.

5. What is retatrutide?

Retatrutide is an investigational triple agonist that activates GIP, GLP-1, and glucagon receptors. Clinical trial results have demonstrated very substantial weight reduction, but the medication remains investigational and is not yet an FDA-approved obesity treatment.

6. How quickly should I lose weight?

Weight loss usually occurs progressively over months. Faster is not necessarily better. The appropriate rate depends on starting weight, medical condition, medication, nutritional status, and preservation of lean body mass.

7. Can GLP-1 medications cause muscle loss?

Substantial weight loss can include loss of lean tissue as well as fat. Adequate protein intake, resistance exercise, and nutritional monitoring are therefore important components of medical weight management.

8. What are the most common side effects?

Gastrointestinal symptoms—including nausea, vomiting, constipation, diarrhea, reflux, and abdominal discomfort—are among the most common. Serious adverse effects can also occur, which is why these medications should be prescribed and monitored appropriately.

9. Will I regain weight if I stop the medication?

Weight regain is common after discontinuation. Obesity is a chronic disease, and patients should develop a long-term maintenance strategy rather than assuming treatment ends automatically when goal weight is achieved.

10. Is compounded semaglutide the same as Wegovy or Ozempic?

No. Compounded products are not FDA-approved drugs and do not undergo the same premarket FDA review for safety, effectiveness, and manufacturing quality.

11. What is “Ozempic face”?

The term describes facial volume loss, hollowing, skin laxity, and other changes that may occur following substantial weight reduction. These changes are better understood as consequences of major weight loss rather than a unique toxic effect of Ozempic.

12. Can loose skin tighten after GLP-1 weight loss?

Some contraction can occur, particularly in younger patients with good skin elasticity and more modest weight loss. Significant excess skin following major weight reduction generally cannot be eliminated by medication, exercise, or skincare products alone.

13. When should I consider plastic surgery after weight loss?

Surgical evaluation is generally most useful when the patient is approaching a stable, maintainable weight and is nutritionally and medically optimized. The timing should be individualized.

14. Should GLP-1 medication be stopped before plastic surgery?

Potential perioperative management depends on the medication, dose, procedure, anesthesia plan, gastrointestinal symptoms, and individual aspiration risk. Recommendations have evolved, so patients should follow the coordinated instructions of their prescribing physician, surgeon, and anesthesia team rather than stopping medication on their own.

15. What plastic surgery procedures are commonly performed after major GLP-1 weight loss?

Depending on anatomy, procedures may include a facelift and neck lift, breast lift, breast augmentation, abdominoplasty, body lift, arm lift, and thigh lift. Treatment should address the patient’s specific pattern of skin laxity, volume loss, and tissue descent rather than the fact that a GLP-1 medication was used.

Key References

1. Pi-Sunyer, X., Astrup, A., Fujioka, K. et al. (2015) ‘A randomized, controlled trial of 3.0 mg of liraglutide in weight management’, New England Journal of Medicine, 373(1), pp. 11–22. doi:10.1056/NEJMoa1411892.
2. Wilding, J.P.H., Batterham, R.L., Calanna, S. et al. (2021) ‘Once-weekly semaglutide in adults with overweight or obesity’, New England Journal of Medicine, 384(11), pp. 989–1002. doi:10.1056/NEJMoa2032183.
3. Rubino, D.M., Greenway, F.L., Khalid, U. et al. (2022) ‘Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: The STEP 8 randomized clinical trial’, JAMA, 327(2), pp. 138–150. doi:10.1001/jama.2021.23619.
4. Jastreboff, A.M., Aronne, L.J., Ahmad, N.N. et al. (2022) ‘Tirzepatide once weekly for the treatment of obesity’, New England Journal of Medicine, 387(3), pp. 205–216. doi:10.1056/NEJMoa2206038.
5. Jastreboff, A.M., Kaplan, L.M., Frías, J.P. et al. (2023) ‘Triple-hormone-receptor agonist retatrutide for obesity—A phase 2 trial’, New England Journal of Medicine, 389(6), pp. 514–526. doi:10.1056/NEJMoa2301972.
6. Wilding, J.P.H., Batterham, R.L., Davies, M. et al. (2022) ‘Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension’, Diabetes, Obesity and Metabolism, 24(8), pp. 1553–1564. doi:10.1111/dom.14725.
7. Aronne, L.J., Bade Horn, D., le Roux, C.W. et al. (2025) ‘Tirzepatide as compared with semaglutide for the treatment of obesity’, New England Journal of Medicine, 393, pp. 26–36. doi:10.1056/NEJMoa2416394.
8. Jastreboff, A.M. et al. (2025) ‘Tirzepatide for obesity treatment and diabetes prevention’, New England Journal of Medicine. doi:10.1056/NEJMoa2410819.
9. U.S. Food and Drug Administration (2026) ‘FDA approves higher dose semaglutide for weight loss and long-term weight maintenance’, FDA, March 2026.
10. Zayas, D. (2023) ‘The differences between Ozempic, Wegovy, Mounjaro, Saxenda, and other popular weight-loss drugs’, RealSelf, updated 8 November 2023.

Acknowledgment

This article is an independent 2026 clinical and plastic-surgery update inspired in part by the patient education article “The Differences Between Ozempic, Wegovy, Mounjaro, Saxenda, and Other Popular Weight-Loss Drugs,” written by Dory Zayas and published by RealSelf, updated November 8, 2023.

The original article provided an accessible overview of the major weight-loss medications available or under investigation at that time. This Naked Truth update incorporates subsequent developments through 2026 and expands the discussion to include body composition, muscle preservation, treatment maintenance, and the aesthetic and reconstructive consequences of major medication-assisted weight loss.

Medical Disclaimer: This article is for educational purposes and does not constitute individualized medical advice. Prescription weight-management medications have indications, contraindications, drug interactions, and potential adverse effects. Decisions regarding obesity treatment and perioperative medication management should be made with appropriately qualified healthcare professionals.